1. Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis {#sec1}
===================================================================

Multiple sclerosis (MS) was initially identified in 1868 by Charcot. This disease often begins in young adulthood with intermittent episodes of neurological dysfunction, including visual impairment, ataxia, motor and sensory deficits, and bowel and bladder incontinence. These are attributable to recurrent inflammatory attacks on the white matter of the brain and spinal cord, which lead to the accumulation of perivascularly distributed inflammatory cells within the brain and spinal cord white matter \[[@B1]\].

Beeton et al. first established an animal model of MS in the 1930s, when they immunized monkeys with a central nervous system (CNS) homogenate to induce what is now known as experimental autoimmune encephalomyelitis (EAE) \[[@B2]\]. Since this pilot animal study, EAE has become the most accepted animal model of MS. In recent decades, pathogenic hypotheses have been investigated and novel therapeutic agents tested in this model in the fields of CNS inflammation and demyelination. Therefore, EAE provides a valuable tool for the investigation of the T-cell-dependent pathogenesis of autoimmune inflammation in the CNS and the orchestration of the autoimmune demyelinating inflammation in the CNS of MS patients. Mice and/or genetically modified mice have also been of fundamental value in the exploration of the complex pathogenesis of MS \[[@B3], [@B4]\]. EAE is undoubtedly the best animal model in which to study autoimmune diseases and particularly the demyelinating diseases of the CNS, such as MS \[[@B5]\].

2. Basic Immunopathogenic Mechanism and the Role of T Cells in EAE and MS {#sec2}
=========================================================================

Myelin basic protein-(MBP)-specific T cells isolated from the peripheral lymphocytes of human individuals with MS and encephalitogenic T cells recovered from circulating autoreactive T cells of either immunized or naïve animals have shown that autoreactive T-cell lines that recognize the encephalitogenic part of MBP in vitro can be distinguished from an unprimed rat T-cell population. This confirms that autoreactive T cells play a central role in the pathology of MS \[[@B6]--[@B8]\]. EAE can also be induced by adoptively transferring an expanded population of myelin-reactive encephalitogenic CD4^+^ (T helper \[Th\]) cells, which allows the further dissection of the immunopathogenic potency of different encephalitogenic CD4^+^ cell populations \[[@B9]\].

In the 1990s, Mosmann and Coffman postulated that Th cells can be classified into two distinct subsets, Th1 and Th2. Th1 cells produce large quantities of interferon *γ* (IFN*γ*), driven by interleukin 12 (IL12), which promotes cellular immunity directed against intracellular pathogens. Alternatively, Th2 cells, which secrete IL4, IL5, IL13, and IL25, are essential in the destruction of extracellular parasites and the mediation of humoral immunity \[[@B10], [@B11]\]. Self-reactive Th1 clones derived in vitro are capable of adoptively transferring EAE to naïve recipients \[[@B12]\]. Increased levels of Th1 cytokines are particularly evident during EAE/MS relapse, whereas increased Th2 cytokines are found during remission in MS patients when compared with control levels \[[@B13]\]. Clinical and hematological symptoms are exacerbated in relapsing/remitting MS patients following the administration of IFN*γ*, and this is also observed in other Th1-type diseases, whereas it is less apparent in Th2 diseases \[[@B14], [@B15]\]. Th1 cells were earlier thought to be pathogenic T cells, whereas Th2 cells were thought to confer an anti-inflammatory potential, constituting protective T cells in both MS and EAE \[[@B16]--[@B19]\].

However, this clear-cut immunodysregulation of the Th1/Th2 balance in EAE and MS may be part of a hidden complex of interactions underlying EAE and MS \[[@B20]\]. The Th1-driven nature of the EAE/MS disease was challenged by the finding that IFN*γ*- and IFN*γ*-receptor-deficient mice, as well as mice that lack other molecules involved in Th1 differentiation, such as IL12p35, IL12 receptor *β*2 (IL12R*β*2), and IL18, were not protected from EAE, but instead were more susceptible to the disease \[[@B21]--[@B25]\]. Unexpectedly, mice deficient in IL12*α* (IL12p35), a component of the Th1 paradigm, are vulnerable to EAE. Similarly, IL12R*β*2-deficient mice develop more severe clinical manifestations of EAE, whereas IL12p40-deficient mice are resistant to EAE \[[@B23], [@B24], [@B26]\]. These discrepancies and conflicting data indicate that an imbalance in the Th1/Th2 milieu cannot explain the overall immunopathogenic mechanisms underlying EAE and MS.

3. Immunopathogenic Role of Th17 Cells and Cytokines in EAE/MS {#sec3}
==============================================================

p19, a novel cytokine heavy-chain homologue of the IL6 subfamily, was discovered as a computational sequence \[[@B27]\]. When the p19 chain is linked to the p40 chain, a subunit of IL12 (another subunit of the IL12 heterodimers is the p35 chain), it forms a novel cytokine designated IL23. Therefore, the deletion of IL12p40 will affect the functions of both IL12 and IL23. Cua and colleagues verified that Il23 but not Il12 is essential for the induction of EAE by generating Il23p19 knockout (KO) mice and comparing them with IL12p35 KO mice \[[@B28]\]. Furthermore, an IL17-producing T-cell subset, driven and expanded by IL23, can pathogenically induce EAE when adoptively transferred into naïve wild-type mice \[[@B29], [@B30]\]. These IL17-producing T cells were dramatically reduced in the CNS of IL23p19-deficient mice. Based on these studies, researchers confidently suggested that IL17-producing CD4^+^ T cells are a distinct and novel Th subset that exacerbates autoimmunity, and designated them Th17 cells \[[@B31], [@B32]\]. Th17 cells are a Th-cell subset distinct from Th1 and Th2 cells in terms of their differentiation, expansion, and effector functions \[[@B33], [@B34]\]. The discovery of Th17 cells further clarifies the cytokine profile of MS \[[@B35]\]. Recently, the levels of IL17 produced by MBP-stimulated peripheral blood cells obtained from MS patients or controls were shown to correlate with the active lesions in MS patients observed with magnetic resonance imaging (MRI) \[[@B36]\].

Like other Th subsets, the Th17 lineage is activated by a specific cytokine milieu. However, IL23 cannot produce Th 17 cells de novo from naïve T cells, and the IL23 receptor (IL23R) is not expressed on naïve T cells \[[@B37]\]. Transforming growth factor *β* (TGF*β*) upregulates IL23R expression, thereby conferring responsiveness to IL23, which confirms that TGF*β* is a critical cytokine in the commitment to Th17 expansion in vitro and in vivo \[[@B38]\]. In mice, TGF*β* together with IL6 can activate antigen-responsive naïve CD4^+^ T cells to develop into Th17 cells \[[@B39]\]. In humans, naïve CD4^+^ cells exposed to IL6, TGF*β*, and IL21 can develop into Th17 cells, and the production of IL23 plays a role in maintaining these Th17 cells \[[@B40], [@B41]\]. Altogether, Th17 cells require IL23, TGF*β*, IL6, and IL1 for their generation. Th17 cells produce IL17A and IL17F, which are upregulated in chronic lesions \[[@B42]\], and IL22, which is also involved in the pathogenesis of MS. Thus, Th17 cells are a recently discovered, unique Th lineage that produces a repertoire of signature cytokines, including IL17A, IL17F, IL21, and IL22, that are essential for the development of autoimmune diseases such as MS \[[@B43]\].

The discovery of transcription factors that are key regulators of the cytokine expression required to launch lineage-specific transcriptional programs has greatly extended our understanding of Th-cell lineage commitment \[[@B44]\]. It has been shown that T-bet and STAT4 program the commitment of the Th1 lineage and Th1 cytokine production \[[@B45]\], whereas GATA-binding protein 3 (GATA3) and STAT6 drive Th2 population expansion and Th2 cytokine production \[[@B46], [@B47]\]. The T-bet and STAT4 (necessary for Th1 differentiation) transcription factors are important in the differentiation of autoimmune T cells in the EAE model \[[@B48]\], and T-bet- and STAT4-deficient mice are resistant to EAE. However, these transcription factors do not mediate the induction of Th17 cells. Instead, in a unique inductive milieu, Th17 differentiation is driven by distinct transcription factors: retinoic acid receptor-related orphan receptor-*γ*t (Ror*γ*t) and Ror*α* \[[@B33], [@B34]\]. Stat3 deletion in T cells also prevents autoimmune uveitis and EAE and increases the expression of IL10 and forkhead box P3 (FoxP3) \[[@B49]\], and the expression of FoxP3 programs the development and functions of Treg cells \[[@B50]\]. In humans, IL23 and IL1*β* also induce the development of Th17 cells expressing IL17A, IL17F, IL22, IL26, IFN*γ*, the chemokine CCL20, and the transcription factor ROR*γ* \[[@B51]--[@B53]\], as illustrated in [Figure 1](#fig1){ref-type="fig"} (adapted from Hirota et al. \[[@B54]\]).

Recent microarray studies of lesions in MS patients demonstrated an increased expression of IL17, confirming that Th17 cells play an important role in the development of inflammation and demyelination and in the eventual damage of the CNS. IL17 is a recently described cytokine produced in humans almost exclusively by activated memory T cells and can induce the production of proinflammatory cytokines and chemokines from parenchymal cells and macrophages. Patients with MS have greater numbers of IL17-mRNA-expressing mononuclear cells in the cerebrospinal fluid (CSF) than in the blood. Previously, no increase in the numbers and expression of IL17 mRNA by mononuclear cells isolated from the CSF was observed in patients with MS, but higher levels of IL17 mRNA were observed in the CSF than in the blood, with the highest levels in the blood detected during clinical exacerbations \[[@B55]\]. These data confirm the pivotal role of IL17 in MS both peripherally and centrally.

4. Recruited and Residential Innate Immune Cells in EAE and MS {#sec4}
==============================================================

Myelin is expressed in the circulation, and other CNS antigens are thought to be expressed in the cervical lymph nodes, which can trigger the conversion of autoaggressive myelin-reactive T cells to pathogenic T cells. Adhesion molecules, the integrins, allow these myelin-reactive T cells to penetrate the blood-brain barrier (BBB) under inflammatory conditions, and in this way, activated and memory T cells can enter the CNS \[[@B56]\]. Autoaggressive myelin-reactive T cells migrate into the CNS, where they recognize their cognate target antigens, and the movement of antigen-presenting cells (APCs) into the CNS is essential for lymphocyte reactivation within the CNS compartment and the initiation of the inflammatory cascade in the development of EAE \[[@B57]\]. Subsequently, inflammatory and immune cells, such as granulocytes and macrophages, are attracted into the CNS parenchyma, where they mediate tissue inflammation, leading to demyelination and tissue damage \[[@B58]\].

The brain was formerly considered an immunoprivileged organ, but this perspective has been revised in the last two decades \[[@B59]\]. Today, we understand that any damage to the CNS can activate immune cells in situ in the CNS, particularly microglial cells. Deshpande et al. demonstrated the transient inactivation of microglial cells via a cell-specific deficiency of CD40 expression, indicating that microglial cells are crucial for maintaining the autoimmune responses in the CNS \[[@B60]\]. The major histocompatibility complex (MHC, also known as "human leukocyte antigens" in humans) class II molecules are only displayed on specialized APCs (e.g., dendritic cells \[DCs\], B cells, and macrophages), whereas MHC class I molecules are expressed by all cells in the inflammatory milieu of the CNS \[[@B61]\]. Microglial cells upregulate the expression of MHC and costimulatory molecules to initiate the generation and maintenance of the inflammatory milieu. DCs seem to play a critical role in antigen presentation to invading T cells and in the release of cytokines and chemokines, thereby guiding the entry of monocytes, lymphocytes, and cells with a phenotype similar to that of DCs into the lesion \[[@B62]\].

Th cells recruit macrophages, which release proinflammatory cytokines and destructive molecules (such as nitric oxide \[NO\], IL1, IL6, tumor necrosis factor *α* \[TNF*α*\], and matrix metalloproteinases (MMPs\]), and CD8^+^ T cells also directly attack MHC class I-expressing cells, such as oligodendrocytes and neurons \[[@B63], [@B64]\]. The secretion of destructive molecules, such as NO and TNF*α*, and the degradation of myelin are consequences of this cascade. TNF receptor 1 (TNFR1) but not TNFR2 signaling is critical for demyelination and the limitation of T-cell responses during immune-mediated CNS disease \[[@B65]\]. This complicated process triggers the recruitment of innate immune cells, generally consisting of T cells, macrophages, and microglia, which in turn mediate demyelination, axonal damage, and lesions.

5. Th17 and Immune Cells In Situ {#sec5}
================================

In autopsy samples from MS patients, the expression of IL17 is evident in perivascular lymphocytes and in astrocytes and oligodendrocytes located in the active areas of CNS lesions. IL17R is also identifiable in acute and chronic MS plaques of patients with MS, suggesting the enrichment of Th17 and CD8^+^ T cells in active MS lesions, and confirming an important role for IL17 in the pathogenesis of MS \[[@B66]\]. Th17 cells are identified by their expression of IL23R and the memory T-cell marker CD45RO in situ. Other markers that have been investigated including the chemokine receptor, CCR6, and RORC variant 2, which is a central transcription factor for Th17-cell development \[[@B42], [@B67]\]. Microarray analysis of MS lesions has also demonstrated increased transcripts of genes encoding inflammatory cytokines, particularly IL6, IL17, and IFN*γ* and associated downstream pathways \[[@B55]\]. A significant increase in IL23 mRNA and protein expression is found in lesion tissues compared with nonlesion tissues. Activated macrophages/microglia have been shown to be important sources of IL23p19 in active and chronically active MS lesions. IL23p19-expressing mature DCs are preferentially located in the perivascular cuffs of active lesions. This data on the expression of IL23p19 in MS lesions improves our understanding of the pathogenesis of MS \[[@B68]\].

There is also evidence that MS endothelial cells express high levels of IL17R and are more permeable to IL17 than are non-MS endothelial cells. Perivascular DCs also express high levels of granzyme B in inflammatory lesions, polarizing naïve CD4^+^ T cells into Th17 cells. These Th17 cells transmigrate efficiently across BBB endothelial cells (BBB-ECs), leading to the destruction of human neurons and initiating CNS inflammation through Th-cell recruitment \[[@B69]\]. Similarly, the expression of IL17R and IL22R on BBB-ECs has been examined in MS lesions, and IL17 and IL22 have been shown to disrupt BBB tight junctions in vitro and in vivo. IL6 transsignaling may also play a role in the autoimmune inflammation of the CNS, mainly by regulating the early expression of adhesion molecules, possibly via cellular networks at the BBB \[[@B70]\]. Ifergan et al. demonstrated that a subset of CD14^+^ monocytes migrate across the inflamed human BBB and differentiate into CD83^+^CD209^+^ DCs under the influence of BBB-secreted TGF*β* and granulocyte-macrophage colony-stimulating factor (GM-CSF). These DCs can produce IL12p70, TGF*β*, and IL6 and promote the proliferation and expansion of distinct populations of Th1 and Th17 cells. The abundance of such DCs in situ is strongly associated with microvascular BBB-ECs within acute MS lesions and with a significant number of Th17 cells in the perivascular infiltrate \[[@B71]\].

Astrocytes play significant physiological roles in CNS homeostasis and act as a bridge between the CNS and the immune system. Astrocytes also contribute to the complex interactions during CNS inflammation. IL17 functions in a synergistic manner with IL6 to induce IL6 expression in astrocytes. Astrocytes upregulate the expression of IL17 and IFN*γ* genes and proteins in T cells, which is consistent with the astrocytes\' capacity to express IL23 subunit p19 and the common IL12/IL23 subunit p40, but not IL12 subunit p35 when these two cell types are cocultured \[[@B72]\]. Das Sarma et al. demonstrated increased IL17RA expression in the CNS of mice with EAE and the constitutive expression of functional IL17RA in mouse CNS tissues. They also identified the expression of IL17RA in both astrocytes and microglia in vitro. In that study, the secretion of the chemokines Mcp1, Mcp5, Mip2, and CxcL1 was upregulated in these cells, suggesting that the upregulation of chemokines by glial cells is the result of IL17A signaling through constitutively expressed IL17RA \[[@B73]\].

Ma et al. demonstrated that the suppressor of cytokine signaling 3 (Socs3) participates in IL17 functions in the CNS as a negative feedback regulator, using mouse models of Socs3 small interfering RNA (siRNA) knockdown and Socs3 deletion. These mice with loss of Socs3 function showed enhanced IL17 and IL6 signaling in astrocytes via the activation of the NF-*κ*B and Mapk pathways, indicating that astrocytes can act as a target of Th17 cells and IL17 in the CNS \[[@B74]\]. Similarly, Kang et al. constructed specific deletion mutants of Act1, a critical component required for IL17 signaling, in mice with EAE to examine CNS inflammation in endothelial cells, macrophages, microglia, and the neuroectoderm (neurons, astrocytes, and oligodendrocytes). In these Act1-deficient mice, Th17 cells showed normal infiltration into the CNS but failed to recruit lymphocytes, neutrophils, and macrophages. Therefore, astrocytes are critical in IL17--Act1-mediated leukocyte recruitment during EAE \[[@B75]\].

Interestingly, Merkler et al. demonstrated that macrophages respond to the Th1 milieu and neutrophils respond to Th17 cytokines in a marmoset monkey model of EAE. They also showed dense accumulations of T and B lymphocytes, MHC-II-expressing macrophages/microglia, and early activated macrophages at the sites of perivascular and parenchymal lesions in the neocortex and subcortical white matter, indicating that the inflammatory response, especially macrophage and microglia activation, may be regulated differently in the gray matter areas of the primate brain \[[@B76]\].

In summary, DCs in the peripheral tissues and microglia in the CNS are responsible for cytokine polarization and the expansion of Th17 cells. The complex interactions of Th17 cells with different DCs, such as microglia, astrocytes, and peripheral DCs (including neutrophils and macrophages), all contribute to the immunopathogenesis of EAE and MS.

6. Reciprocal Interactions of Cytokines on Th Subsets in EAE/MS {#sec6}
===============================================================

IL1R KO mice have impaired Th17 cells and are protected from EAE \[[@B77]\], and IL1*β* increases the susceptibility to and progression of relapse onset in MS \[[@B78]\], implying a role for IL1*β* in the development of EAE and MS. EAE was abolished by a virus-expressing IL4 but not by a virus-expressing IL10 in chronic relapsing EAE. Therefore, the cytokine environment was converted from a disease-promoting IL23-producing condition to a disease-limiting IL4-producing condition by the local expression of IL4 from a Herpes simplex virus vector delivered to the brain \[[@B79]\]. Moreover, the increased expression of IL4 in glial cells was associated with the reduced severity of EAE \[[@B80]\], suggesting that the upregulation of Th2 cytokines inhibits the propagation of the inflammation of EAE/MS by encephalitogenic Th17 cells. CD4^+^CD25^+^Foxp3^+^ T cells, well-known regulatory T cells (Tregs), retain the potential to inhibit the autoimmune response, and protect against inflammatory injury. TGF*β* is a key cytokine in the generation of Tregs. Tregs are not only primarily involved in the regulation of Th17 cells but can also regulate the functions of Th1/Th2 cells \[[@B81]\]. A distinction has been drawn between the generation of pathogenic Th17 cells that induce autoimmunity and the generation of Tregs that inhibit autoimmune tissue injury \[[@B39]\].

Although EAE was once considered a classical Th1 disease, it has been proposed that it is predominantly Th17 driven. Recently, Singh et al. demonstrated that the overexpression of IL17 in T cells did not exacerbate EAE. Moreover, genetic and antibody studies have indicated that the absence of IL17A or IL17F does not reduce the incidence or severity of EAE. The collective findings of IL17 and IFN*γ* studies indicate that their roles may depend on the nature of the immune response and that the IL17 that occurs in the brain may overcome the inhibitory effect of IFN*γ*, which generally prevents inflammation at that site \[[@B82]\]. When pure Th17 cells from myelin oligodendrocyte glycoprotein-(MOG-) immunized mice, polarized with TGF*β* to deplete any IFN*γ* production, are adoptively transferred to mice, they do not induce EAE, suggesting that the reciprocal interactions among Th17-related cytokines enrol and activate the involvement of associated immune cells. Interestingly, when Th17 cells are combined with Th1 cells, they can fully induce EAE disease \[[@B83]\]. Liu et al. also demonstrated that the loss of STAT3 by Th cells results in an intrinsic developmental defect that renders STAT3^−/−^ mice resistant to CNS inflammatory diseases. STAT3 is required for the production of IL17 by Th17 cells, the generation of double positive T cells expressing IL17 and IFN*γ*, and T cell trafficking into CNS tissues. This suggests that STAT3 may be a therapeutic target for modulating CNS autoimmune diseases, and that Th1 cells can facilitate the entrance of Th17 cells into the CNS during EAE \[[@B84]\].

An encephalitogenic Th1 cell line that induces the recruitment of host Th17 cells to the CNS during the initiation of EAE has been reported \[[@B49]\]. Stromnes et al. showed significant differences in the regulation of inflammation in the brain and spinal cord, depending on different Th17/Th1 ratios, by demonstrating that specific T-cell populations targeting different myelin epitopes are characterized by different Th17/Th1 ratios in EAE \[[@B85]\]. Therefore, Th1 cells have the potential to reciprocally regulate Th17 cells during EAE.

IL21 is a type I four-*α*-helix bundle cytokine that belongs to the IL2 family and functions as a "growth hormone"-like cytokine. After the antigen-responsive differentiation phase, Th17 cells enter the amplification stage, and IL21 plays a pivotal role in the expansion and differentiation of the Th17 lineage, providing an autocrine and paracrine stimulus for Th17 cells \[[@B41], [@B86]\]. During clonal expansion, IL21 also promotes IL23R expression in differentiated Th17 cells, which plays an important role in the stabilization of the Th17 lineage in the presence of IL23 \[[@B87]\]. Although no effects were observed when Il21 was administered after EAE progression, the administration of IL21 boosted natural killer (NK) cell functions before the induction of EAE, including the secretion of Ifn*γ*. Therefore, IL21, by affecting NK cells, has various effects during the initiation and progression of EAE \[[@B88]\].

Alternatively, IL27, an IL12/IL23 family member, is a negative regulator of Th17 cell differentiation and can prevent inflammatory demyelination in the EAE model \[[@B44]\]. IL27 drives the expansion and differentiation of IL10-producing Tr1 cells by inducing the expression of three key molecules: the transcription factor c-MAF, the cytokine IL21, and ICOS. Moreover, IL27-driven c-MAF expression transactivates the production of IL21, which acts as an autocrine growth factor for the expansion and/or maintenance of IL27-induced Tr1 cells. ICOS also promotes IL27-driven Tr1 cells. Each of these elements is essential, because the loss of c-MAF, IL21 signaling, or ICOS reduces the frequency of IL27-induced differentiation of Tr1 cells ([Figure 1](#fig1){ref-type="fig"}) \[[@B89]\]. Exacerbation of EAE was demonstrated in IL27-deficient mice, and interestingly, Il27-treated mice had markedly reduced CNS inflammatory infiltration, indicating the downregulation of Th17 phenomena \[[@B90]\].

Recently, a novel effector T-cell subset, Th9 cells, has been identified, and the ability of this T-cell subset to induce EAE is currently being investigated. Jäger et al. generated Mog-specific Th17, Th1, Th2, and Th9 cells in vitro to directly characterize their encephalitogenic potency after their adoptive transfer. They found that Mog-specific Th1, Th17, and Th9 cells, but not Th2 cells, induce EAE. Interestingly, each T-cell subset induced disease in a distinct pathological manner, suggesting that the different effector Th subsets that induce EAE do so differently and implying that the pathological heterogeneity in MS lesions might be partly attributable to various characteristics of myelin-reactive effector T cells \[[@B91]\]. The authors also suggested that MS might be a disease caused by multiple distinct myelin-reactive effector cells. The disease induced by Th17 cells in some animals exhibited symptoms atypical of EAE, including ataxia, severe imbalance, and weight loss associated with high mortality. Some animals had a mixture of atypical and typical EAE symptoms. When cells were recovered from the CNS, it appeared that the transferred Th9 cells produced IFN*γ*. The identities of the other cell populations did not seem to drift after their in vivo transfer \[[@B92]\].

Nowak et al. recently demonstrated that like other T cells cultured in the presence of TGF*β*, Th17 cells produce IL9. Th17 cells generated in vitro with IL6 and TGF*β* and ex vivo-purified Th17 cells both produced IL9. Data show that IL9 neutralization and IL9R deficiency attenuate the disease, and this correlated with reductions in Th17 cells and IL6-producing macrophages in the CNS. These authors also confirmed the role of IL9 in the development and progression of EAE and implicated Il9 as a Th17-derived cytokine that contributes to inflammatory disease \[[@B93]\].

Together, Th2 cells, Tr1 cells, and Tregs exert repressive effects on Th17 cells, and Th9 cells have a stimulatory effect on Th17 cells, suppressing EAE and MS. However, Th1 cells play dual roles in EAE.

7. Clinical Applications, Limitations, and the Future of Immunomediated Therapies for MS {#sec7}
========================================================================================

Our understanding of the pathophysiology and neurodegenerative processes of MS has led to the development of novel therapeutic strategies. Since the early 1990s, disease-modifying drugs have been introduced for the selective management of MS, including IFN*β* and glatiramer acetate (GA), which have become the standard treatment for relapsing/remitting MS \[[@B94]\]. Most recommendations previously made by the Multiple Sclerosis Therapy Consensus Group (MSTCG) on the use of disease-modifying drug therapies remain valid \[[@B95], [@B96]\]. Hermmer and Hartung have published an apparent review of the development of rational therapies in MS \[[@B97]\]. Therefore, we will discuss four domains of novel immunomediated therapeutics used for MS and their current status.

The first domain includes immunosuppressive agents, such as mitoxantrone, laquinimod (ABR-215062), cladribine (Mylinax ), and teriflunomide (probably via the suppression of TNF*α* and IL2 production). The second domain includes immunomodulatory agents: (1) cytokine inhibitors such as IFN*β*; (2) agents that deplete specific immune cell subsets, such as alemtuzumab (a human monoclonal antibody \[mAb\] that targets CD52 expressed by T and B cells, producing long-term T-cell depletion) \[[@B98], [@B99]\] and rituximab (which targets CD20 to deplete human B cells) \[[@B98], [@B100]\]; (3) agents that selectively block coreceptors and costimulators, such as daclizumab (an anti-CD25 mAb that inhibits activated T cells and induces regulatory immune cells) \[[@B101]\]. The third domain involves the development of migration-modifying therapies: (1) agents that affect adhesion molecules, such as natalizumab (an mAb that blocks very late antigen 4 \[VLA-4\]) and (2) sphingosine 1-phosphate receptor (S1PR) agonists: fingolimod (FTY720). The fourth domain includes neuroprotective agents associated with immunomodulation, including broad-spectrum immunomodulators such as statins, PPAR agonists (e.g., pioglitazone, gemfibrozil), the sex hormone estriol (E3), fumarate, minocycline, and erythropoietin (EPO), all of which have been effective in the treatment of both EAE, and MS. IFN*β* has been clinically introduced to treat patients with MS based on its ability to shift a Th1-mediated response to a Th2-mediated response \[[@B91]\]. However, microarray studies have indicated that a number of genes in patients with MS are upregulated by the cytokines associated with the differentiation of cells into Th1 lymphocytes rather than into Th2 lymphocytes, suggesting that this shift may not be the only therapeutic mechanism of IFN*β* in MS \[[@B102]\]. IFN*β* therapy also reduces IL23 mRNA levels \[[@B103]\]. IFN*β* inhibits human Th17 cell differentiation, so the Th17 axis could be another target of IFN*β* therapy \[[@B104]\]. IFN*β*-mediated IL27 production by innate immune cells has been shown to play a critical role in the immunoregulatory role of IFN*β* in EAE by inhibiting Th17 cells in EAE mice and MS patients \[[@B90], [@B105], [@B106]\]. Besides, Galligan et al. evidence further that IFN*β*(−/−) mice exhibited an earlier disease onset and a more rapid progression of EAE compared to IFN*β*(+/+) mice of EAE and IFN*β*(−/−) mice of EAE had increased numbers of CD11b(+) leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the CNS with augmentation of autoreactive T cells,suggesting that IFN-*β* acts to suppress the production of autoimmune-inducing Th17 cells during the development of disease as well as modulating proinflammatory \[[@B107]\]. In addition, the therapeutic effect of IFN*β* is probably attributable to the induction of the regulatory cytokine IL10 \[[@B103]\]. Furthermore, Axtell et al. design a delicate study to further clarify the role of IFN*β* in MS/EAE \[[@B108]\]. Likewise, They demonstrate that IFN*β* was effective in reducing EAE symptoms transferred by Th1 cells transfer but exacerbated disease by Th17 cells transfer and effective treatment of IFN*β* in Th1-induced EAE correlated with augmented IL10 production; differently, in Th17-induced EAE, the amount of IL10 was unaffected by treatment of IFN*β*. Likewise, a high IL17F level in the serum of people with RRMS is associated with fail of IFN*β* therapy. This characteristic of IFN*β* might contribute to explore some logical biomarkers for predictive assessment of the response to a popular therapy for MS \[[@B108], [@B109]\]. Although, B cells may have a dual role in the pathogenesis of MS that they contribute to the induction of the autoimmune response but also mediate the resolution of the CNS inflammatory infiltrate \[[@B110], [@B111]\]. However, Ramgolam et al. demonstrate further that supernatants transferred from IFN*β*-1b-treated B cells inhibited Th17 cell differentiation, as they suppressed gene expression of the RORC and IL-17A and secretion of IL-17A. Likewise, IFN*β*-1b also induces B cells\' IL-10 secretion which may mediate their regulatory potent \[[@B112]\]. Thus, IFN*β*-1b exerts its therapeutic effects at least in part by targeting B cells\' functions that contribute to the autoimmune pathogenesis of RR MS, which may uncover extra mechanisms of the B-cell contribution to the autoimmune effects and provide novel targets for future selective treatment of MS \[[@B112]\].

Glatiramer acetate (GA; Copaxone; copolymer 1) exerts a clinical response in MS patients via its modulation of IFN*γ* and IL4 by reducing the expression of IFN*γ* and ensuring the stable expression of IL4 in anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) \[[@B113]\]. Moreover, GA enhances the suppressive effects of Tregs in both EAE and MS \[[@B114], [@B115]\]. Studies of human DCs have shown that GA modulates the production of inflammatory mediators without affecting DC maturation or immunostimulatory potential. DCs exposed to GA secrete low levels of the Th1-polarizing factor IL12p70 in response to lipopolysaccharide and triggering of the CD40 ligand \[[@B116]\]. Human DCs exposed to GA also induce IL4-secreting effector Th2 cells and increase their expression of IL10 \[[@B117]\]. These results show that APCs, including DCs, are essential for the GA-mediated shift in Th-cell phenotypes and indicate that DCs are an important target of the immunomodulatory effects of GA.

Patients with MS show a threefold to fourfold increase in the expression of the *α*4 subunit of the integrin VLA-4, which is normally expressed on activated lymphocytes, monocytes, and other cell types in the CSF and circulation \[[@B118]\]. Elovaara et al. confirmed that methylprednisolone reduces the adhesion molecules in the blood and CSF in patients with MS \[[@B119]\], implying that targeting leukocyte trafficking may be a possible therapeutic strategy for MS \[[@B120]\]. Therefore, natalizumab, a humanized mAb directed against the VLA-4 adhesion complex, has been introduced into the treatment of MS and reduces the risk of sustained progression of disability and the rate of clinical relapse in patients with relapsing MS \[[@B121]\]. However, during clinical trials, two natalizumab-treated MS patients developed progressive multifocal leukoencephalopathy (PML), which resulted in the voluntary removal of the drug from the market in February 2005 \[[@B122], [@B123]\]. A retrospective safety evaluation was subsequently conducted, and natalizumab was consequently returned to the market as a monotherapy in July 2006 for the treatment of relapsing MS; however, there were 111 cases of PML reported subsequently in natalizumab-treated MS patients as of April 2011 \[[@B124]\]. More evidently, the risk of developing PML for a MS patient on natalizumab (Tysabri) is almost 100 times higher if the patient (1) has been taking the drug for more than two years, (2) has a prior history of immunosuppressant use, and (3) tests positive for antibodies to the JC virus \[[@B125]\], compared to a patient with none of these three risk factors \[[@B126]\]. Instead, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents \[[@B127]\]. Nevertheless, natalizumab use must be restricted to the indicated patients.

Mitoxantrone, a cytotoxic drug with immunomodulatory properties, is used to treat progressive forms of MS \[[@B128]\]. Mitoxantrone increases the ex vivo production of the Th2 cytokines IL4 and IL5, but with no significant changes in IFN*γ*, TNF*α*, IL10, or IL17 expression by PBMCs or CD4^+^ T cells, indicating that the immunomodulation afforded by mitoxantrone treatment in MS acts through the enhancement of Th2-type cytokines \[[@B129]\].

Currently, a head-to-head race for approval had initially developed between two under spotlight oral immunomodulatory agents---fingolimod and cladribine ([Figure 2](#fig2){ref-type="fig"}) \[[@B130]\]. Fingolimod (FTY720/Gilenya, Novartis), an S1PR modulator \[[@B131]\], is under the spotlight because it has completed phase III trials \[[@B132]\] and has been approved by the US Food and Drug Administration as the first oral, first-line treatment for relapsing MS \[[@B133], [@B134]\]. S1PR is mainly expressed by immune cells, neuronal cells, endothelial cells, and smooth muscle cells \[[@B135]--[@B138]\]. The key roles of S1PR in angiogenesis, neurogenesis, and the regulation of immune cell trafficking, endothelial barrier function, and vascular tone were demonstrated with the genetic deletion of S1pr in a murine model \[[@B139]--[@B141]\]. The immunomodulatory effect of fingolimod acts in two pathways. In one pathway, it inhibits the function of S1PR, which facilitates the CC-chemokine receptor 7-(CCR7-) mediated retention of lymphocytes in the lymph nodes, including naïve T cells and central memory T cells, but not effective memory T cells. This significantly reduces the infiltration of inflammatory cells into the CNS \[[@B142], [@B143]\] and reduces the numbers of autoreactive Th17 cells that are recirculating via the lymph and blood to the CNS \[[@B144]--[@B146]\]. The second pathway prohibits neuroinflammation via the modulation of the S1PR1 expressed on oligodendrocytes, neurons, astrocytes, and microglia \[[@B75], [@B147], [@B148]\]. Another oral immunomodulatory drug Cladribine (2-chlorodeoxyadenosine) is a synthetic chlorinated deoxyadenosine analog \[[@B149]\] that is activated by intracellular phosphorylation in specific cell types, resulting in preferential and sustained reduction of peripheral T and B lymphocytes, mimicking the immune-deficient status of hereditary adenosine deaminase deficiency \[[@B150]\]. Orally administered cladribine shows significantly efficacy in patients with RR-MS \[[@B151]\]. Relative to placebo, oral cladribine reduces relapses by 55--58% and has an impact on disability progression and all MRI outcome markers in patients with RR-MS \[[@B151]--[@B153]\]. Nevertheless, to exactly weight the benefits of both novel immunomodultory agents against the potential risks is necessary and must be monitored continually.

These advances in identifying unique therapeutic targets for MS have instigated numerous phase II and phase III clinical trials, for example, trials of various mAbs, including those directed against CD52 (alemtuzumab), CD25 (daclizumab), and CD20 (rituximab), and trials of disease-modifying therapies, such as teriflunomide, laquinimod, and fumarate \[[@B134], [@B154]\]. For example, alemtuzumab, a humanized mAb, targets the surface molecule CD52 on all T-cell populations and other cellular components of the immune system, such as thymocytes, B cells, and monocytes \[[@B155]\].

Offner reported that estrogen and its derivatives exert neuroimmunoprotective effects against EAE and that E2 upregulates the expression of Foxp3 and Ctla4, which contribute to the activity of Tregs, suggesting the therapeutic application of estrogen to MS \[[@B156]\]. Papenfuss et al. also demonstrated that estriol (E3), a pregnancy-specific estrogen, has therapeutic efficacy in MS and EAE and they confirmed that E3 protects mice against EAE by inducing DCs to increase their expression of inhibitory costimulatory markers (PD-L1, PD-L2, B7-H3) and deviate towards a Th2 phenotype \[[@B157]\].

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily, which includes receptors for steroids, retinoids, and thyroid hormones, all of which are involved in the immune response \[[@B158]\]. Natarajan et al. demonstrated that PPAR*γ* agonists inhibit EAE by blocking IL12 production, IL12 signaling, and Th1 cell differentiation \[[@B159]\]. Kanakasabai et al. further demonstrated that the PPAR*δ* agonists ameliorate EAE by blocking IFN*γ* and IL17 production by Th1 and Th17 cells. The inhibition of EAE by PPAR*δ* agonists is also associated with reductions in IL12 and IL23 and increases in IL4 and IL10 expression in the CNS and lymphoid organs. This indicates that PPAR*δ* agonists modulate the Th1 and Th17 responses in EAE, and suggests their use in the treatment of MS and other autoimmune diseases \[[@B160]\].

Minocycline, an oral semisynthetic tetracycline antibiotic, can penetrate the CNS and has interesting pleiotropic biological functions and neuroprotective effects, including in demyelinating diseases such as MS \[[@B161]\]. Nikodemova et al. have shown that minocycline attenuates EAE in rats by reducing T-cell infiltration into the spinal cord and downregulating LFA-1 on T cells, but without modifying the production of dominant cytokines \[[@B162]\]. Zabad et al. demonstrated in a cohort study the impact of oral minocycline on clinical and MRI outcomes and serum immune molecules during the 24 months of open-label minocycline treatment. No relapses occurred between months 6 and 24, and the levels of the p40 subunit of IL12 were elevated during the 18 months of treatment, which might have counteracted the proinflammatory effects of IL12R. The downregulation of MMP9 activity was reduced by minocycline treatment \[[@B163]\].

Brines et al. have demonstrated that EPO mediates neuroprotection against experimental ischemic brain injury \[[@B164]\]. Agnello et al. have shown that EPO exerts an anti-inflammatory effect that ameliorates EAE \[[@B165]\]. Yuan et al. also demonstrated that EPO retains its immunomodulatory capacity in both the periphery and the inflamed spinal cord by promoting a massive expansion of Treg cells, inhibiting Th17 polarization and abrogating the proliferation of antigen-presenting DCs \[[@B166]\]. We observed significantly reduced levels of both Th1 and Th17 cells in the CNS and a significantly increased proportion of splenic Tregs in EPO-treated Mog-EAE mice. We also demonstrated that MOG-specific T-cell proliferation was suppressed in the EPO-treated group \[[@B167]\].

The immunomodulatory mechanisms of immunomediated therapeutic agents are not fully understood. Here, we report our current understanding of the immunomodulatory effects of clinically proven and clinically tried agents, and of potential candidate agents, such as decoy receptor 3 (DcR3). We have selectively reviewed their immunomodulation in EAE and MS. Demjen et al. showed that the neutralization of CD95L (FasL) promoted axonal regeneration and functional improvement in an injured animal model, suggesting that this therapeutic strategy may constitute a potent future treatment for human spinal injury \[[@B168]\]. DcR3 is a recognized member of the TNFR superfamily and is predominantly expressed in tumor cells, allowing them to evade immune attack \[[@B169]\]. DcR3 is a soluble receptor that binds to members of the TNF family and can competitively inhibit the binding of TNF to TNFRs \[[@B170]\]. FasL, LIGHT, and TNF-like molecule 1A (TL1A) are all confirmed ligands of DcR3 \[[@B171], [@B172]\]. When DcR3 binds to FasL, it inhibits FasL-induced apoptosis \[[@B169]\]. It has also recently been shown that DcR3 counteracts the effects of Th17 cells by interfering with FasL-Fas interactions \[[@B173]\]. We have demonstrated that DcR3 ameliorates EAE by directly counteracting inflammation and downregulating Th17 cells in situ \[[@B174]\], implying that DcR3 downregulates the Th17 response and inhibits the inflammation of the CNS in situ during EAE by blocking ligand-receptor interactions, such as Fas-FasL, DR2--LIGHT, and/or DR3--TL1A. Therefore, we introduce DcR3, another immunomodulatory molecule, as a potential candidate for consideration in the clinical treatment of MS.

In summary ([Figure 2](#fig2){ref-type="fig"}), these immunomodulatory agents and neuroprotective therapies for MS have great value as clinical agents, to be tested in clinical trials or preclinical studies, and in the development of novel therapeutic strategies for MS \[[@B161]\].

8. Concluding Remarks {#sec8}
=====================

MS is the most common disabling CNS disease in young adults. It is characterized by recurrent relapses and/or progression, which are attributable to multifocal inflammation, demyelination, and axonal pathology within the brain and/or spinal cord \[[@B175]\]. The effector Th cells play a well-recognized role in the initiation of autoimmune tissue inflammation, and these autoreactive effector CD4^+^ T cells have an established association with the pathogenesis of this disorder \[[@B17]\]. However, in models thought to be driven by Th1 cells, mice lacking the hallmark Th1 cytokine IFN*γ* were not protected from EAE but tended to display enhanced susceptibility to this disease \[[@B26]\]. The identification of Th17 cells has shed light on this apparent discrepancy. Like Th1 cells, polarized Th17 cells have the capacity to cause inflammation and autoimmune disease. A deficiency of the Th17-related cytokine IL23, but not of the Th1-related cytokine IL12, induces resistance to EAE, implying that Th17 cells are the chief contributors to EAE/MS \[[@B28]\], whereas Th1 cells can consistently transfer EAE disease \[[@B16], [@B17]\]. Komiyama et al. demonstrated that EAE was significantly suppressed in Il17^−/−^ mice, manifested as delayed onset, reduced maximum severity, ameliorated histological changes, and early recovery \[[@B176]\]. However, the outcomes have varied when the differentiation and/or functions of Th17 cells have been blocked in clinical trials of human autoimmune diseases, with notable success only in psoriasis and Crohn\'s disease, but negative results in relapsing/remitting MS. The strategy of inhibiting the Th17 response has had even less support in preclinical studies in animal models \[[@B177]\].

These data raise the questions of whether MS is mediated solely by Th1 cells or solely by Th17 cells, whether it is mediated by both pathways, or whether perhaps it is mediated by neither pathway \[[@B175]\]. There is growing evidence that autoreactive T cells (particularly Th1 and Th17 cells) participate in the pathophysiology of MS. Although the exact roles of Th1 and Th17 cells in the development of MS lesions are not well understood, it appears that both these effector T-cell populations can cause CNS inflammation and demyelinating lesions in MS and EAE \[[@B50], [@B178]\].

Our increasing understanding of the immunopathogenic roles of Th1, Th2, and Th17 cells and Tregs in MS/EAE should facilitate the development of novel immunomodulatory therapeutic approaches to MS \[[@B179], [@B180]\]. The treatment of MS has always been hampered by the untoward adverse effects caused by immunosuppression with agents such as natalizumab \[[@B127]\]. Currently approved disease-modifying treatments achieve their effects primarily by blocking the proinflammatory response in a nonspecific manner. Their limited clinical efficacy calls for a more differentiated and specific therapeutic approach. We can confidently say that IFN*β*, GA, and mitoxantrone are fairly clinically effective for MS patients. The addition of estrogen(s) or minocycline has also shown benefits in the treatment of MS. We have established the protective effects of DcR3 and EPO against EAE \[[@B174], [@B181]\], but further evidence is required before they can be used clinically for the treatment of MS. More immunomodulatory therapeutic agents are currently in clinical trials, including fingolimod (FTY720), alemtuzumab, and rituximab add-on therapies \[[@B182]\]. The extensive clinical application of these potential novel immunomodulatory therapeutic agents will be under close scrutiny in the near future.
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![Current schedule of T-helper-cell differentiation. When naïve CD4^+^TCR*αβ* ^+^ T lymphocytes, classified by their low expression of CD44, absence of CD25, and high levels of CD62L, encounter their cognate antigens, they can differentiate into several previously identified effector subsets. It is likely that several "master" transcription factors, individually required for T-cell differentiation towards one of the end effector stages, are initially expressed upon engagement of the TCR with costimulatory receptors. Each transcription factor drives a specific set of genes required for lineage commitment and the expression of signature cytokines and negatively affects alternative pathways. However, the local microenvironment is the driving force that determines the outcome of the differentiation course. Th1 cells are established in the presence of IFN*γ* and IL12 and signaling via STAT1 and STAT4, resulting in the expression of the master transcription factor T bet. Th2 cells depend on IL4 and STAT6 for the increased expression of GATA3, whereas the simultaneous presence of TGF*β* results in the development of Th9 cells, utilizing an undefined master transcription factor. The presence of TGF*β*, with IL2 signaling via STAT5, is known to generate, at least in vitro, inducible Treg, which utilize FOXP3 like those Treg generated in the thymus. Again, it is TGF*β* in combination with IL6 signaling via STAT3 that drives the expression of ROR*γ*t, resulting in the differentiation of Th17 cells. However, the initiation of the developmental program of these T helper subsets may not be completed in the presence of only these driving cytokines. Several additional factors may be required for their subsequent functional maturation or may be responsible for the fine tuning of their effector phases. Several of these factors are indicated, together with the characteristic cytokine profiles of each subset (adapted from \[[@B54]\]).](CDI2012-970789.001){#fig1}

![Multiple sclerosis immunopathogenesis and therapeutic targets. Immature dendritic cells (DCs) are central players in the innate immune response and are involved in the maintenance of peripheral tolerance by promoting the suppressor Treg and anti-inflammatory Th2-cell responses. Abnormally activated (mature) antigen-presenting DCs can be found in patients with multiple sclerosis (MS). This activation results in the increased production of proinflammatory cytokines, which lead to the aberrant activation of Th1 and Th17 proinflammatory responses. Activated encephalitogenic adaptive immune effectors (such as Th1 cells, Th17 cells, CD8^+^ cells, and B cells) express surface molecules that allow them to penetrate the blood-brain barrier and to enter the central nervous system (CNS). The presence of autoreactive immune effectors, together with abnormally activated CNS astrocytes and microglia, leads to the increased production of reactive oxygen species, excitotoxicity, autoantibody production, and direct cytotoxicity, which are all involved in the demyelination and axonal and neuronal damage that is present in patients with MS. Potential therapeutic interventions at different levels of the immunopathological cascade are shown in the filled yellow boxes (cytotoxic T lymphocytes \[CTL\]; interferon *γ* \[IFN*γ*\]; IL2 receptor \[IL2R\]; major histocompatibility complex class II \[MHC II\]; matrix metalloproteinases \[MMPs\]; nitric oxide \[NO\]; oligodendrocyte \[ODG\]; sphingosine 1-phosphate receptor \[S1PR\]; transforming growth factor *β* \[TGF*β*\]; tumor necrosis factor \[TNF\]; regulatory T cells \[Treg\]; vascular cellular adhesion molecule 1 \[VCAM1\]; very late antigen 4 \[VLA-4\] (This figure was adapted and partly revised from \[[@B161]\].).](CDI2012-970789.002){#fig2}
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